MediWound Ltd. (MDWD)
| Market Cap | 175.06M -13.7% |
| Revenue (ttm) | 11.86M -40.3% |
| Net Income | -20.18M |
| EPS | -2.25 |
| Shares Out | 12.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,748 |
| Open | 13.52 |
| Previous Close | 13.53 |
| Day's Range | 13.40 - 13.72 |
| 52-Week Range | 13.40 - 20.30 |
| Beta | 0.16 |
| Analysts | Strong Buy |
| Price Target | 29.83 (+119.99%) |
| Earnings Date | Aug 13, 2026 |
About MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other ... [Read more]
Financial Performance
In 2025, MediWound's revenue was $16.96 million, a decrease of -16.14% compared to the previous year's $20.22 million. Losses were -$23.88 million, -20.99% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price target is $29.83, which is an increase of 119.99% from the latest price.
News
MediWound Earnings Call Transcript: Q2 2026
Q2 2026 saw progress in EscharEx's phase III trial and record NexoBrid U.S. sales, though revenue declined year-over-year due to BARDA timing. Full-year revenue guidance of $24–$26 million was reaffirmed, with H2 expected to be stronger as new government contracts and development programs ramp up.
MediWound Earnings release: Q2 2026
MediWound released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MediWound Slides: Corporate presentation
MediWound has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract fo...
MediWound to Report Second Quarter 2026 Financial Results
MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd.
MediWound price target lowered to $22 from $25 at Alliance Global
Alliance Global lowered the firm’s price target on MediWound (MDWD) to $22 from $25 and keeps a Buy rating on the shares. The company’s Q1 results saw lower revenue and…
MediWound price target lowered to $32 from $33 at Oppenheimer
Oppenheimer lowered the firm’s price target on MediWound (MDWD) to $32 from $33 and keeps an Outperform rating on the shares after the company reported Q1 results and provided a…
MediWound Earnings Call Transcript: Q1 2026
Q1 2026 saw lower revenue due to BARDA timing and shipment delays, but gross margin improved. EscharEx and NexoBrid programs advanced, with a new $197M BARDA contract and reaffirmed 2026 revenue guidance of $24–26M, expecting a strong second half.
MediWound Earnings release: Q1 2026
MediWound released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
MediWound reports Q1 EPS (23c), consensus (66c)
Reports Q1 revenue $1.48M, consensus $3.37M. “During the first quarter, we continued to advance both our strategic and operational priorities,” said Ofer Gonen, CEO of MediWound (MDWD). “Enrollment co...
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue ...
MediWound Slides: Corporate presentation
MediWound has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
MediWound to Report First Quarter 2026 Financial Results
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive bi...
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings support o...
MediWound says Vericel awarded ten-year contract valued at up to $197M
MediWound (MDWD) announced that Vericel (VCEL), its exclusive distributor of NexoBrid in North America, has been awarded a ten-year contract valued at up to $197M by the U.S. Biomedical Advanced…
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
MediWound management to meet with Maxim
Meeting to be held on March 17-18 hosted by Maxim.
MediWound Files Annual Report on Form 20-F
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announce...
MediWound Earnings Call Transcript: Q4 2025
2025 saw major clinical and manufacturing milestones, with EscharEx and NexoBrid advancing and revenue guidance reaffirmed for 2026–2028. Despite lower 2025 revenue due to US government delays, the balance sheet was strengthened and long-term growth drivers remain intact.
MediWound Annual report: Q4 2025
MediWound has published its Q4 2025 annual report on March 5, 2026.
MediWound Earnings release: Q4 2025
MediWound released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
MediWound reports Q4 EPS (56c), consensus (61c)
Reports Q4 revenue $1.867M, consensus $2.09M. “We entered 2026 with two strategic growth drivers,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD). “Our Phase III VALUE trial of EscharEx…
MediWound sees FY26 revenue $24M-$26M, consensus $26.21M
The Company reaffirms its revenue guidance of $24-26 million for 2026.
MediWound sees FY27 revenue $32M-$35M, sees FY28 revenue $50M-$55M
The Company reaffirms its revenue guidance of $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028. Guidance assumes continued support from BARDA and the U.S. Department…